Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 40,029 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

40,029 Papers indexed
1,440 Papers AI scored
40,029 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

40029 results
B
Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review.
PMID 38641057 Published: 2024-04-17 Ingested: 2026-08-02 12:02 AM Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
AI -
Standard 71.9
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.9/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 22.0; sample size: 60.0; recency: 80.0; abstract quality: 100.0.

B
AI -
Standard 71.9
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.9/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 22.0; sample size: 60.0; recency: 80.0; abstract quality: 100.0.

B
Experiences of adult survivors of childhood cancer in a randomized cardiovascular health promotion trial: a qualitative report from the Childhood Cancer Survivor Study.
PMID 37253902 Published: 2023-05-30 Ingested: 2026-08-02 12:02 AM Journal of cancer survivorship : research and practice
AI -
Standard 71.9
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.9/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 32.0; sample size: 20.0; recency: 65.0; abstract quality: 100.0.

B
AI -
Standard 71.88
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.9/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 71.9; sample size: 50.0; recency: 90.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.9/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 54.3; sample size: 20.0; recency: 100.0; abstract quality: 100.0.

B
[Analysis of predictive effect of European treatment and outcome study long term survival score on survival outcomes in children with chronic myeloid leukemia of chronic phase].
PMID 39327962 Published: 2024-10-02 Ingested: 2026-08-02 12:02 AM Zhonghua er ke za zhi = Chinese journal of pediatrics
AI -
Standard 71.86
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.9/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 34.3; sample size: 70.0; recency: 90.0; abstract quality: 100.0.

B
Prognostic Impact of Telomere Maintenance Mechanisms in Neuroblastoma.
PMID 42848963 Published: 2026-10-08 Ingested: 2026-10-10 09:15 AM Journal of clinical oncology : official journal of the American Society of Clinical Oncology
AI -
Standard 71.85
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.9/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 56.8; sample size: 70.0; recency: 100.0; abstract quality: 100.0.

Previous
Page 555 of 3336
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic